Abstract: Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural ?-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.

Abstract: The present invention relates to a method of producing a recombinant polypeptide in a genetically modified host cell. A host cell and a vector for transforming such host cell is also provided.

Abstract: An alkali metal-containing, organometallic product, which is hydrocarbon-soluble, is prepared by reacting an organo-alkali metal reactant in which the alkali metal atom is bonded to a carbon atom, e.g. cyclohexyl-lithium, with a di(organooxy)-alkaline earth metal reactant, e.g. di-n-butoxy-magnesium, in an organic solvent at about -20.degree. to +120.degree.C. The organo-alkali metal reactant can be prepared by reacting an organo halide with an alkali metal, and this can be done in situ, i.e. in the presence of the di(organooxy)-alkaline earth metal reactant. The organometallic product has approximately the same chemical reactivity as the organo-alkali metal reactant from which it is prepared, but is more soluble in hydrocarbon solvents.